Vesiculate, founded in 2023, is at the forefront of resolving a critical challenge in nanoparticle analysis. By providing precisely engineered vesicle standards, the company addresses the long-standing issue of mismatched calibration in particle analysis instruments. Traditional methods using solid "beads" have often led to discrepancies in data due to differences with the soft, complex nanoparticles analyzed in therapeutic development.
Vesiculate offers Syncles™, synthetic vesicle standards, to ensure reliable data by aligning instrument calibration closely with the properties of therapeutic nanoparticles like extracellular vesicles and lipid nanoparticles. This innovation helps standardize workflows and ensures consistent data integrity, enabling researchers to validate instrument performance with accuracy.
The company's recent $20.00K Seed Round investment from UNSW Founders highlights investor confidence in their potential to set a new benchmark in nanoparticle analysis. As a vertically integrated provider, Vesiculate oversees every step of vesicle design, synthesis, and validation, underscoring their commitment to quality and reliability in the field of manufacturing.
